

Supplementary Table 4. Neoadjuvant and adjuvant treatment for rectal cancer patients

Variable	Total (n = 76)	LARS ^a			P-value
		No (n = 41)	Minor (n = 10)	Major (n = 25)	
Neoadjuvant ^b					
CCRT	23 (30.3)	11 (26.8)	4 (40.0)	8 (32.0)	0.700 ^c
None	53 (69.7)	30 (73.2)	6 (60.0)	17 (68.0)	
Adjuvant ^b					
Chemotherapy	36 (47.4)	22 (53.7)	2 (20.0)	12 (48.0)	0.159 ^d
CCRT	1 (1.3)	0 (0)	0 (0)	1 (4.0)	
None	39 (51.3)	19 (46.3)	8 (80.0)	12 (48.0)	

LARS, low anterior resection syndrome; CCRT, concurrent chemoradiotherapy.

^aPatients with a LARS score of 0–20, 21–29, and 30–42 were regarded as having no LARS, minor LARS, and major LARS, respectively. ^bThere was no case of radiotherapy alone in the neoadjuvant or adjuvant setting. ^cPearson chi-square test. ^dFisher exact test.